(Q42278411)

19 October 2017

Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management (English)

1 reference

interstitial lung disease

19 October 2017

1 reference

P Camus

1

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

British Journal of Cancer

19 October 2017

1 reference

19 October 2017

91 Suppl 2

1 reference

19 October 2017

S1-2

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602060

19 October 2017

0 references

cites work

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Chemotherapy-induced lung disease

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic–uremic syndrome due to gemcitabine

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

26 October 2017

Drug-induced lung injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Fatal pulmonary toxicity resulting from treatment with gemcitabine

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Targeting targeted therapy

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Pulmonary Toxicity due to Chemotherapy How is the Risk and Benefit from ZD1839 Treatment against Non-Small Cell Lung Cancer?

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Acute lung injury as a possible adverse drug reaction related to gefitinib

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Severe acute interstitial pneumonia and gefitinib

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750812

Severe acute interstitial pnuemonia and gefitinib

17 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602060

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study

1 reference

12 December 2020

Docetaxel and interstitial pulmonary injury

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602060

1 reference

Dimensions Publication ID

19 October 2017

0 references

1 reference

19 October 2017

PubMed publication ID

15340371

1 reference